Table 1 Application of upper gastrointestinal tract complications (UGIC) risk estimations to the populations of patients included in the control groups (exposed to traditional non-steroidal anti-inflammatory drugs) for the Vioxx Gastrointestinal Outcomes Research (VIGOR), Celecoxib Long-term Arthritis Safety Study (CLASS), and Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET) trials
From: Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications
Study | Age mean | Female % | Ulcer History % | Aspirin % | Reported Incidence Per 1,000 p-y | Estimated Incidence Per 1,000 p-y |
|---|---|---|---|---|---|---|
VIGOR [21] | 58 | 80 | 7.8 | 0 | 8.6* | 7.0 |
CLASS [22] | 60 | 69 | 9.6 | 20 | 14.5 | 9.5 |
TARGET [23] | 63 | 76 | 3.5 | 24 | 9.1 | 8.1 |